Gilenya (fingolimod): Updated recommendations to minimise the risk of drug-induced liver injury (DILI)
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Gilenya
|
| Active substance |
Fingolimod
|
| Therapeutic area (MeSH) |
Multiple Sclerosis
|
| Procedure number |
EMEA/H/C/PSUSA/00001393/202002
|
| Regulatory outcome |
Variation
|
| DHPC type |
Periodic safety update report
|
| Human ATC code |
L04AA27
|
| Dissemination date |
10/11/2020
|